> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Neuronetics Moves Ad Money Into 8 New Clinic Sales Reps, Citing Better Return
- URL: https://www.bullished.co/neuronetics-moves-ad-money-into-8-new-clinic-sales-reps-citing-better-return-a7c64b4b/
- Published: 2026-11-04T15:27:04.000Z
- Updated: 2026-11-04T15:27:04.000Z
- Description: The company says field reps beat consumer ads on return and will lift its team from 20 to 28 at no added cost.
- Author: Matteo Parrino
- Tags: Earnings, STIM, Industry: Healthcare

[Neuronetics](https://www.bullished.co/tag/stim/), which makes the NeuroStar transcranial magnetic stimulation system and runs Greenbrook treatment clinics, will shift part of its consumer advertising budget into field sales reps, CEO Dan Reuvers said on the company's third-quarter earnings call Wednesday. He said the plan adds eight reps to a base of 20 by sometime in the first quarter, with "no incremental cost."

## Why reps beat ads

Reuvers said the company's data show field salespeople deliver the better return and give it more control over patient acquisition cost and yield. Reps can use pharma data to find prescribers in primary care and psychiatry offices near Greenbrook clinics, and the patients they refer "come in much better qualified."

Patients arriving through consumer ads who have not failed two medications cannot be treated, Reuvers said, and they can clog intake teams. "It's not magic," he said, describing the plan as repurposing ad dollars to sponsor more salespeople.

The company plans to start in the fourth quarter and expects the new reps to be fully ramped and contributing meaningfully by mid-2027.

## Empty chairs at the clinics

Reuvers said clinic occupancy runs from about 25% at the bottom to 75% at the best performers, and the company wants to lift the bottom quartile. Filling existing capacity remains an important profitability lever, he said.

Greenbrook revenue was about $26 million in the quarter, up over 20% from a year earlier, as better revenue cycle management and Spravato growth both contributed. Total revenue was [about $42 million](https://www.globenewswire.com/news-release/2026/11/04/3395221/0/en/neuronetics-reports-third-quarter-2026-financial-and-operating-results.html?ref=bullished.co), up over 12%, and Neuronetics reported income from operations of half a million dollars against a loss of $7.3 million a year earlier. NeuroStar revenue was $15.8 million, up about 2%, on a record quarter of system sales.

## Betting on a psychedelic launch

Reuvers said Neuronetics is preparing with Compass Pathways for the anticipated launch of its psychedelic therapy for treatment-resistant depression. Compass has said it expects to finish its FDA submission in about two weeks, with launch expected in the first half of 2027.

An analyst from B. Riley asked about rollout. Reuvers said the company has not shared how many sites will start, but expects a hub-and-spoke model rather than offering it in all 84 Spravato clinics. Early on, he said, single case agreements will likely rule the day while coverage matures.

Neuronetics shares traded at $2.59, up about 15% from the prior close, in Wednesday trading.

Compass's FDA submission is due in about two weeks, and the new Greenbrook reps begin ramping in the fourth quarter.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Neuronetics: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/neuronetics-q3-earnings-snapshot/616-043f92ca-af74-40ea-a1b1-bf969881235d?ref=bullished.co) — Associated Press
- [Neuronetics: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/neuronetics-q3-earnings-snapshot/616-043f92ca-af74-40ea-a1b1-bf969881235d?ref=bullished.co) — Associated Press
- [Neuronetics: Q3 Earnings Snapshot | wfaa.com](https://www.wfaa.com/article/syndication/associatedpress/neuronetics-q3-earnings-snapshot/616-043f92ca-af74-40ea-a1b1-bf969881235d?ref=bullished.co) — Associated Press
- [Neuronetics: Q3 Earnings Snapshot | khou.com](https://www.khou.com/article/syndication/associatedpress/neuronetics-q3-earnings-snapshot/616-043f92ca-af74-40ea-a1b1-bf969881235d?ref=bullished.co) — Associated Press
- [Neuronetics Reports Third Quarter 2026 Financial and](https://www.globenewswire.com/news-release/2026/11/04/3395221/0/en/neuronetics-reports-third-quarter-2026-financial-and-operating-results.html?ref=bullished.co) — globenewswire.com

### More on Neuronetics

- [Neuronetics Posts Operating Profit, Yet Projects It Will Miss A Revenue Test On Its $65.0 Million Loan](https://www.bullished.co/neuronetics-posts-operating-profit-yet-projects-it-will-miss-a-revenue-test-on-its-65-0-e9e8265a/)
- [Neuronetics Posts $0.5 Million Operating Profit As Greenbrook Clinics Climb 20.1%](https://www.bullished.co/neuronetics-posts-0-5-million-operating-profit-as-greenbrook-clinics-climb-20-1-646d6421/)

[All Neuronetics (STIM) coverage →](https://www.bullished.co/tag/stim/)